Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide-Reference-Cited by-同舟云学术

Inhibition of gastrin-stimulated growth of gastrointestinal tumour cells by octreotide and the gastrin/cholecystokinin receptor antagonists, proglumide and lorglumide

Published:1992-01 Issue:8-9 Volume:28 Page:1462-1467
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Watson Susan A.,Morris David L.,Durrant Lindy G.,Robertson John F.,Hardcastle Jack D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Possible role of gut hormones in cancer;Townsend,1987

2. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin;Watson;Int J Cancer,1989

3. Evidence for autocrine growth stimulation of cultured colon tumour cells by a gastrin/cholecystokinin-like peptide;Hoosein;Exp Cell Res,1990

4. Characterisation of a human gastric adenocarcinoma, MKN45G, which is associated with intracellular gastrin, and its response to anti-gastrin antibodies;Watson;Gut,1990

5. Intracellular gastrin in human Gastrointestinal (GI) tumour cells: a possible autocrine/paracrine role;Watson;JNCI,1991

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential of the gastric motility drug lorglumide in prostate cancer imaging;European Journal of Pharmaceutical Sciences;2012-04

2. The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers;Protein & Peptide Letters;2009-12-01

3. The CCK-2/gastrin splice variant receptor retaining intron 4 transactivates the COX-2 promoter in vitro;Regulatory Peptides;2007-12

4. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin;Journal of Pineal Research;2005-10

5. Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment;Current Pharmaceutical Design;2004-07-01